ClinicalTrials.gg

Program

ninerafaxstat

Also written as “IMB-1018972” and “Ninerafaxstat 200mg MR”.

Its studies are mostly in Cardiomyopathy, Hypertrophic · Angina Pectoris · Diabetes Mellitus, Type 2 · Ischemia, led by Imbria Pharmaceuticals.

Furthest: phase 2, since Mar 8, 20205 company-led studies, 1 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Imbria Pharmaceuticals51 open or runningphase 2since Mar 8, 2020Mar 8, 2020Dec 2026phase 2 · NCT07023614

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 8, 2020First study: phase 2 study in Angina PectorisFirst studyNCT04306237 · United States
  2. Mar 18, 20213 phase 2 studiesNCT04826185, NCT04826172, NCT04826159
  3. Jun 9, 2025Phase 2 study in Cardiomyopathy, HypertrophicNCT07023614 · 165 planned · United States, Austria, Belgium and more

Ahead

  1. Dec 2026Primary completion: phase 2 study in Cardiomyopathy, HypertrophicNCT07023614

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07023614Cardiomyopathy, Hypertrophic · United States, Austria, Belgium and more2RecruitingDec 2026165
NCT04826185Non-obstructive Hypertrophic Cardiomyopathy · United States, United Kingdom2CompletedSep 18, 202367
NCT04826172Ischemia · Denmark, Finland, Sweden2CompletedSep 21, 202358
NCT04826159Diabetes Mellitus, Type 2 · United Kingdom2CompletedAug 6, 202449
NCT04306237Angina Pectoris · United States2WithdrawnFeb 20250

How it is read

Names in the registry

  • “IMB-1018972”, 4 entries
  • “Ninerafaxstat 200mg MR”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.